Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoki Terada

Showing results (181-190 of 185) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 185 results.
International Journal of Clinical Oncology|July 8, 2024
Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvementTokiyoshi Tanegashima, Masaki Shiota, Takahiro Kimura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate CancerKei Mizuno, Takayuki Sumiyoshi, Takatsugu Okegawa, et al.
Cancer Science|April 29, 2022
Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancerMasaki Shiota, Dai Takamatsu, Takahiro Kimura, et al.
Cancer Science|June 19, 2021
Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancerMasaki Shiota, Naoki Terada, Hiroshi Kitamura, et al.
Cancer Science|November 7, 2020
Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patientsMasaki Shiota, Naoki Terada, Toshihiro Saito, et al.
Pageof 19

Showing results (181-190 of 185) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 185 results.
International Journal of Clinical Oncology|July 8, 2024
Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvementTokiyoshi Tanegashima, Masaki Shiota, Takahiro Kimura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate CancerKei Mizuno, Takayuki Sumiyoshi, Takatsugu Okegawa, et al.
Cancer Science|April 29, 2022
Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancerMasaki Shiota, Dai Takamatsu, Takahiro Kimura, et al.
Cancer Science|June 19, 2021
Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancerMasaki Shiota, Naoki Terada, Hiroshi Kitamura, et al.
Cancer Science|November 7, 2020
Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patientsMasaki Shiota, Naoki Terada, Toshihiro Saito, et al.
Pageof 19